News

23.09.2021

An article from the 'Märkische Allgemeine' reports on companies from Brandenburg, which develop therapeutics and diagnostics for COVID-19.

Hennigsdorf, August 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin, publishes an interview with CEO Dr. Ahmed Sheriff.

The innovative and cutting-edge therapy CRP apheresis convinces.

Avoiding serious tissue damage in myocardial infarction and preserving cardiac output. A clinical study on CRP apheresis after myocardial infarction showed significantly positive results. Other cases in clinical practice support these results. Similarly, 9 Covid-19 patients - one before and the others in intensive care - have recovered. The majority were already on artificial ventilation. Unfortunately, about 50 percent of these patients die under normal conditions when treated according to guidelines.

08.06.2021
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.

19.05.2021

The Sat.1 morning show has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.

18.05.2021

ZDF has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.

07.05.2021

In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.

The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.

02.08.2021

Recently a new case report has been published in Frontiers in Immunology about the first COVID-19 patient at the onset of a severe COVID-19 course. Small heads-up: it turned out amazingly well!

27.07.2021

Another case report has been published on the successful treatment of a young, ventilated COVID-19 patient in Immenstadt. One very effective CRP apheresis was sufficient. Afterwards, the patient's clinical parameters were back to normal.

12.07.2021

In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.

11.03.2021

Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.

10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.

12.09.2020
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).

Dezember 2020
Here is a “short” teaser to record our webinar on anti-inflammatory strategies for COVID-19, which is intended to provide an overview of what we believe to be the most exciting topics, key messages and areas of conflict at the event.

14.12.2020
Pentracor GmbH recently held its first webinar with renowned physicians from Germany and Switzerland to discuss the increasingly clear relevance of the pathological function of CRP in the inflammatory, severe phase of COVID-19.

21.05.2021
On the Neutron podcast, CRP apheresis was introduced and explained, and Dr. Ahmed Sheriff was interviewed. The focus was on the use of the therapy in COVID-19 patients.

19.05.2021
As part of the Lunch & Learn event series of the Biotechnologieverbund Berlin-Brandenburg (bbb), Dr. Ahmed Sheriff presented the PentraSorb^® CRP and reported on its use at Klinikum Havelhöhe, where almost all COVID-19 patients are now treated with CRP apheresis. Afterwards there was an exciting discussion.

07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.

20.03.2021
Pentracor organizes a Care Symposium about CRP apheresis at the 13th ISFA & E-ISFA Congress.

Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.

18.11.2020
He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.

01.10.2020
We are pleased to announce that Prof. Dr. Jan Torzewski of the Klinikum Kempten and Klinik Immenstadt from the Klinikverbund Allgäu has been nominated for the German Medical Award.

27.04.2019

Das Poster “Selective CRP apheresis as a new treatment option in STEMI: Final results of the CAMI1 Study” von der CAMI1-Studiengruppe wurde als Highlight der DGK Jahrestagung im Bereich “Interventionelle Kardiologie” vorgestellt. 

25.07.2018

The abstract "Selective CRP apheresis as a new therapeutic option in the treatment of acute myocardial infarction (STEMI)" by Dr. Wolfgang Ries was awarded as one of the 10 best at the 10th Annual Meeting of the German Society for Nephrology (DGfN) 2018.

07.04.2018

The poster "Selective CRP apheresis as a new treatment option in acute myocardial infarction (CAMI1 study)" by Prof. Dr. Christoph Garlichs was awarded a poster prize at the 84th Annual Meeting of the DGK.

10.08.2021

Pentracor recently joined the BVMed business association, which represents the interests of the German medtech industry and, in particular, medtech SMEs. BVMed represents around 220 industrial and commercial companies in the medical technology sector. Among others, the world's 20 largest medical device manufacturers in the consumer goods sector are organized in BVMed.

03.12.2020
To meet the strict hygiene requirements for emergency overnight stays, the Berliner Stadtmission has an increasing need for Corona rapid tests for guests and staff.

14.10.2020
Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.

25.08.2010
On August 25, 2010, Dr. Ahmed Sheriff together with Birgit Vogt, Dr. Rudolf Kunze, Stephan Hiller and Dr. Bernd Wegener founded Pentracor GmbH to implement the idea of CRP apheresis for acute inflammation-driven diseases such as myocardial infarction.